Tapentadol in Chronic Malignant Tumour Related Pain

Inclusion Criteria: * Participants must have signed an Informed Consent Form. * At least 18 years of age. * Male and non-pregnant, non-lactating female subjects. Sexually active women must be post menopausal, surgically sterile, or practicing an effective method of birth control before entry and throughout the trial. Female participants of child-bearing potential must have a negative pregnancy test at enrollment. * Within 24 weeks of either full completion or completion of the double-blind treatment period (Visit 8) of KF5503/15 trial performed in participants with moderate to severe chronic malignant tumor related pain. * Participant is, in the opinion of the investigator, expected to continue to have an overall positive benefit/risk ratio from continuing analgesic treatment within this trial. * Participant must be willing to take tapentadol prolonged release (PR) throughout their participation in the trial. Exclusion Criteria: * History of alcohol and/or drug abuse. * The participant has a clinically significant disease other than cancer that in the Investigator's opinion may affect the safety of the participant. * Employees of the investigator or trial center or family members of the employees or the investigator. * Known to or suspected of not being able to comply with the protocol and the use of tapentadol prolonged release (PR). * Concurrent participation in another trial (except for participation in the KF5503/15 trial) or planning to be enrolled in another clinical trial during the course of this trial. * Previous participation in another trial between the end of KF5503/15 and enrollment into the current trial, KF5503/52. * History of seizure disorder, epilepsy, traumatic brain injury, stroke or transient ischemic attack. * Known history and/or presence of cerebral tumors or metastases. * Rapidly escalating pain or pain uncontrolled by therapy and was previously treated with maximum dose level of Investigational Medicinal Product. * Participant is taking any prohibited concomitant medications. * Uncontrolled hypertension. * Known moderate or severe hepatic impairment. * Known severe renal impairment. * Clinically relevant history of hypersensitivity, allergy, or contraindications to tapentadol or its excipients.